Share on StockTwits

Marrone Bio Innovations (NASDAQ:MBII) CEO Pamela G. Marrone bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $5.29 per share, for a total transaction of $5,290.00. Following the completion of the transaction, the chief executive officer now directly owns 727,806 shares of the company’s stock, valued at approximately $3,850,094. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Wednesday. They now have a $6.60 price target on the stock. Separately, analysts at Robert W. Baird downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $12.00 price target on the stock, down previously from $15.00. Finally, analysts at Piper Jaffray downgraded shares of Marrone Bio Innovations from an “overweight” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $11.00 price target on the stock, down previously from $19.00. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $14.43.

Shares of Marrone Bio Innovations (NASDAQ:MBII) traded up 7.21% during mid-day trading on Thursday, hitting $5.65. The stock had a trading volume of 233,231 shares. Marrone Bio Innovations has a 52-week low of $5.13 and a 52-week high of $20.00. The stock has a 50-day moving average of $9.63 and a 200-day moving average of $12.03. The company’s market cap is $117.4 million.

Marrone Bio Innovations (NASDAQ:MBII) last announced its earnings results on Thursday, August 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.03. On average, analysts predict that Marrone Bio Innovations will post $-1.77 earnings per share for the current fiscal year.

Marrone Bio Innovations, Inc is a provider of bio-based pest management and plant health products. Bio-based products are consists of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.